ATYR Stock Analysis: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.52
0.02 (3.08%)
▲
5d:
-45.33%
30d:
-39.13%
90d:
-47.15%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 20, 2026
TODAY
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
14 traders called ATYR this week
93% bullish • 2 bearish
93% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATYR is down 45.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATYR is down 45.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.52, which is considered oversold relative to its 30-day fair value range of $0.64 to $0.93.
Technical Outlook: Technically, ATYR is showing sideways momentum. Immediate support is located at $0.40, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ATYR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.50 (+381.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATYR is showing sideways momentum. Immediate support is located at $0.40, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ATYR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.50 (+381.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.64 -
$0.93
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 381.2% below Wall St target ($2.50)
- WARNING: Recommendation downgraded due to -45.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.64 -
$0.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$1.05
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.89
Wall Street Target
$2.50
(+381.2%)
Share & Embed Analysis
Last updated: May 18, 2026 10:55 PM ET
Data refreshes hourly during market hours. Next update: 11:55 PM
Data refreshes hourly during market hours. Next update: 11:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill Marie Broadfoot
SELL
1558 shares
2026-02-04
Nancy Denyes
SELL
1118 shares
2026-02-04
Sanjay Shukla
SELL
3745 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 58 HOLD |
